Literature DB >> 21945175

CCR4 dependent migration of Foxp3+ Treg cells to skin grafts and draining lymph nodes is implicated in enhanced graft survival in CD200tg recipients.

Kai Yu1, Zhiqi Chen, Ismat Khatri, Reginald M Gorczynski.   

Abstract

We have previously reported that transgenic overexpression of CD200 in either mouse skin graft donors or recipients significantly enhances skin allograft survival. By focused microarray analysis we showed this enhanced graft survival is associated with increased expression of Foxp3, GITR, CTLA-4 and CCR4 mRNA, all genes related to T(reg) cell induction/function, and of Gata3, IL-4, IL-5, IL-13, and somewhat surprisingly, of T-bet, INF-γ and granzyme b. Gene-specific real-time PCR and immunohistochemistry analysis confirmed an increase in Foxp3(+) T(reg) cells in both the skin grafts and draining lymph nodes (DLNs) of CD200(tg) recipient mice at both 7/14 days post engraftment, as well as providing evidence for increased expression of the ligands for CCR4, CCL17 and CCL22 in both locations. Following lentivirus-mediated shRNA treatment of Dox-treated CD200(tg) mice to attenuate expression of CCR4 mRNA, the increased localization of T(reg) cells in skin/DLN of CD200(tg) recipients was abolished, and the enhanced graft survival similarly reversed. We conclude that enhanced CCR4 dependent migration of Foxp3(+) T(reg) to grafted tissue and DLNs is an essential step in the graft prolongation afforded by overexpression of CD200. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21945175     DOI: 10.1016/j.imlet.2011.09.002

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

1.  Marginal zone CD169+ macrophages coordinate apoptotic cell-driven cellular recruitment and tolerance.

Authors:  Buvana Ravishankar; Rahul Shinde; Haiyun Liu; Kapil Chaudhary; Jillian Bradley; Henrique P Lemos; Phillip Chandler; Masato Tanaka; David H Munn; Andrew L Mellor; Tracy L McGaha
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-03       Impact factor: 11.205

Review 2.  Apoptotic cell responses in the splenic marginal zone: a paradigm for immunologic reactions to apoptotic antigens with implications for autoimmunity.

Authors:  Tracy L McGaha; Mikael C I Karlsson
Journal:  Immunol Rev       Date:  2016-01       Impact factor: 12.988

Review 3.  Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation.

Authors:  Claudia Selck; Margarita Dominguez-Villar
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

4.  Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.

Authors:  Wei Sun; Wei-Jin Li; Fan-Qin Wei; Thian-Sze Wong; Wen-Bin Lei; Xiao-Lin Zhu; Jian Li; Wei-Ping Wen
Journal:  Oncotarget       Date:  2016-06-21

Review 5.  Migration and homeostasis of regulatory T cells in rheumatoid arthritis.

Authors:  Konstantin Kotschenreuther; Shuaifeng Yan; David M Kofler
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

6.  Over-Expression of CD200 Protects Mice from Dextran Sodium Sulfate Induced Colitis.

Authors:  Zhiqi Chen; Kai Yu; Fang Zhu; Reginald Gorczynski
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

7.  IL-33 drives the production of mouse regulatory T cells with enhanced in vivo suppressive activity in skin transplantation.

Authors:  Kento Kawai; Masateru Uchiyama; Joanna Hester; Fadi Issa
Journal:  Am J Transplant       Date:  2020-09-15       Impact factor: 9.369

8.  Immunotherapy via PD-L1-presenting biomaterials leads to long-term islet graft survival.

Authors:  María M Coronel; Karen E Martin; Michael D Hunckler; Graham Barber; Eric B O'Neill; Juan D Medina; Enrico Opri; Claire A McClain; Lalit Batra; Jessica D Weaver; Hong S Lim; Peng Qiu; Edward A Botchwey; Esma S Yolcu; Haval Shirwan; Andrés J García
Journal:  Sci Adv       Date:  2020-08-28       Impact factor: 14.136

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.